Table 4. Type of EGFR mutations observed in our series.
SANGER | ||||
---|---|---|---|---|
Type of mutation | Ex | Num cases a | Predicted role for TKI treatment | References |
G719A | 18 | 1 | Response | [1,2,15,17] |
Exon 19 deletions | 19 | 10 | Response | [1,2,8,13,15-17] |
L858R | 21 | 3 | Response | [1,14-16] |
T790M | 20 | 1 | Resistance | [19-21] |
NGS | ||||
Type of mutation | Ex | Num cases b | Predicted role for TKI treatment | References |
G719A | 18 | 1 | Response | [1,2,15,17] |
Exon 19 deletions | 19 | 14 | Response | [1,2,8,13,15-17] |
L858R | 21 | 5 | Response | [1,14-16] |
P772S | 20 | 1 | Response (Putative) | [18] |
T790M | 20 | 1 | Resistance | [19-21] |
R831H | 21 | 1 | Resistance | [22] |
F795S | 20 | 1 | Undefined (reported in CRC and SCC of the oral cavity) | [62,65] |
T785I | 20 | 1 | Undefined (reported in NSCLC) | [63,66] |
V845M | 21 | 1 | Undefined (reported in adrenocortical carcinoma) | [64] |
P691T, K708N, G721W, S752F, D807G | 18, 19, 20, 21 | 1 each | Mutations not previously described | - |
aIn one case double mutations were observed; bin six cases double/multiple mutations were observed. TKI, tyrosine kinase inhibitor; CRC, colorectal carcinoma; SCC, squamous cell carcinoma; NSCLC non small cell lung carcinoma.